Stock listing

LS Exchange:A3C31Y GENinCode PLC Aktie

German listing (LS Exchange) of GENinCode PLC · home listing LSE:GENI

Follow GENinCode PLC into a list and get an email when it puts out news.

Home listing price · LSE:GENI

0.55p GBX (pence) -0.05 (-8.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:GENI

Past year -76.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.50p – 0.60p GBX (pence)Nov 20, 2026
Volume
2.20M sharesNov 20, 2026
Market cap
£4.14M GBPAt the close on Nov 20, 2026 · price × 753.0M shares outstanding
52-week range
0.50p – 4.90p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£21,018 GBPMedian day 1.36M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
GENinCode PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:GENI · Home0.55p GBX (pence)-0.05 (-8.3%)2,203,3050.60p0.60p0.50p0.60pClose on Nov 20, 2026
Frankfurt:9PL€0.0030 EUR-0.0020 (-40.0%)——€0.0060—€0.0050Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:GENI · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
0.55p-0.05-8.3%0.60p0.60p0.50p2,203,305
0.60p0.000.0%0.60p0.60p0.55p55,528
0.60p0.000.0%0.577p0.65p0.55p81,684
0.60p0.000.0%0.65p0.65p0.56p136,022
0.60p+0.02+3.4%0.55p0.65p0.55p1,680,337
0.58p-0.02-3.3%0.65p0.65p0.55p142,203
0.60p0.000.0%0.65p0.65p0.56p368,649
0.60p0.000.0%0.63p0.65p0.55p30,706
0.60p0.000.0%0.583p0.65p0.56p2,060,524
0.60p+0.02+3.4%0.598p0.60p0.55p5,455,341
0.58p+0.03+5.5%0.58p0.619p0.50p5,033,418
0.55p-0.10-15.4%0.607p0.70p0.518p7,991,461
0.65p0.000.0%0.65p0.70p0.60p2,320,003
0.65p-0.01-1.5%0.70p0.70p0.60p296,697
0.66p0.000.0%0.65p0.70p0.621p821,230
0.66p-0.04-5.7%0.65p0.67p0.62p1,402,098
0.70p0.000.0%0.652p0.75p0.652p311,276
0.70p-0.025-3.4%0.80p0.80p0.65p5,985,976
0.725p0.000.0%0.745p0.80p0.65p1,297,669
0.725p+0.10+16.0%0.60p0.85p0.60p7,904,894
0.625p-0.025-3.8%0.65p0.65p0.60p564,504
0.65p-0.025-3.7%0.675p0.70p0.612p4,233,805
0.675p+0.075+12.5%0.60p0.70p0.575p3,865,641
0.60p-0.025-4.0%0.625p0.65p0.561p1,374,835
0.625p0.000.0%0.625p0.636p0.625p79,436
0.625p0.000.0%0.625p0.65p0.60p109,277
0.625p0.000.0%0.625p0.637p0.601p529,109
0.625p0.000.0%0.625p0.65p0.601p220,851
0.625p0.000.0%0.625p0.65p0.60p1,007,932
0.625p0.000.0%0.625p0.65p0.60p277,433
0.625p0.000.0%0.625p0.65p0.588p360,021
0.625p-0.05-7.4%0.675p0.70p0.605p2,336,078
0.675p-0.025-3.6%0.70p0.72p0.65p2,764,493
0.70p0.000.0%0.70p0.75p0.65p311,245
0.70p0.000.0%0.70p0.75p0.65p966,851
0.70p0.000.0%0.70p0.75p0.65p2,249,511
0.70p0.000.0%0.70p0.75p0.65p1,356,034
0.70p-0.175-20.0%0.80p0.80p0.636p22,954,144
0.875p0.000.0%0.875p0.899p0.854p94,424
0.875p0.000.0%0.875p0.90p0.854p718,082
0.875p0.000.0%0.875p0.90p0.85p1,801,413
0.875p0.000.0%0.875p0.90p0.85p1,359,025
0.875p0.000.0%0.875p0.90p0.854p99,515
0.875p-0.025-2.8%0.90p0.92p0.85p2,012,713
0.90p+0.05+5.9%0.85p0.95p0.80p5,287,333
0.85p+0.025+3.0%0.825p0.85p0.80p1,012,902
0.825p-0.025-2.9%0.85p0.85p0.80p999,259
0.85p0.000.0%0.85p0.90p0.80p3,569,064
0.85p0.000.0%0.85p0.90p0.80p4,093,902
0.85p-0.10-10.5%0.95p0.97p0.813p5,699,294
0.95p0.000.0%0.95p1.00p0.90p2,733,624
0.95p0.000.0%0.95p1.00p0.90p4,532,754
0.95p0.000.0%0.95p1.00p0.90p391,667
0.95p-0.075-7.3%1.025p1.10p0.90p2,894,231
1.025p+0.075+7.9%0.95p1.10p0.90p3,273,306
0.95p-0.025-2.6%0.975p1.00p0.90p943,134
0.975p-0.025-2.5%1.00p1.05p0.95p583,564
1.00p-0.05-4.8%1.05p1.10p0.95p3,756,693
1.05p+0.10+10.5%1.025p1.25p0.95p21,428,256
0.95p+0.075+8.6%0.875p0.98p0.825p5,708,782
0.875p-0.025-2.8%0.875p0.899p0.852p329,414
0.90p+0.025+2.9%0.875p0.90p0.85p3,578,240
0.875p0.000.0%0.875p0.90p0.85p1,150,041
0.875p0.000.0%0.875p0.90p0.856p2,102,440
0.875p-0.025-2.8%0.891p0.891p0.85p987,749
Ticker
LS Exchange:A3C31Y
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

Holding(s) in Company

Nov 6, 2026

Closed 0.60p (+3.4%) on Nov 6, 2026

Half-year Financial Report

Sep 29, 2026

Closed 0.70p (-20.0%) on Sep 29, 2026

Additional Subscription

Feb 6, 2026

Closed 1.15p (0.0%) on Feb 6, 2026

Result of Retail Offer

Jan 26, 2026

Closed 1.05p (-4.5%) on Jan 26, 2026

Result of Placing and Subscription

Jan 22, 2026

Closed 1.15p (-37.8%) on Jan 22, 2026

Retail Offer

Jan 21, 2026

Closed 1.15p (-37.8%) on Jan 22, 2026

Placing and Subscription

Jan 21, 2026

Closed 1.15p (-37.8%) on Jan 22, 2026

Collaboration with Sohin Genetics

Dec 17, 2025

Closed 2.80p (-1.8%) on Dec 17, 2025

All GENinCode PLC news

GENinCode PLC on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
14 in the last 12 months · 68 in all · newest Nov 6, 2026 · oldest 2021
Calls
10 calls with a replay · 10 with a transcript · latest Jun 10, 2026

Where GENinCode PLC is listed

ListingExchangeCountryCurrency
LSE:GENI · Home listingLSEUnited KingdomGBX
LS Exchange:A3C31Y · This pageLS ExchangeGermanyEUR
Lang & Schwarz:A3C31YLang & SchwarzGermanyEUR
Frankfurt:9PLFrankfurtGermanyEUR
Stuttgart:9PLStuttgartGermanyEUR

Valuation

EV/sales 0.7× against a median of 1.6×: 5th lowest of 10 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£2.19M GBP
P/E
Loss
EV/sales
0.7×
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
50.0%
Operating margin
−191.6%
Net margin
−185.5%
Debt to equity
0.1×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
GENinCode PLC · LSE:GENIUS$5.42MUS$2.86Mn/a0.7×n/a2.0×−185.5%0.1×n/a
Milton Essex S.A. · NEWCONNECT:MTNUS$6.07MUS$6.06Mn/a17,573×n/a0.5×n/a0.0×n/a
iXensor Co., Ltd. · TPEX:6734US$6.01MUS$5.63Mn/a6.9×n/a23.1×−174.7%0.9×n/a
Cizzle Biotechnology Holdings PLC · LSE:CIZUS$5.70MUS$5.59Mn/an/an/an/an/an/an/a
AcouSort AB · OMXSTO:ACOUUS$5.69MUS$4.76Mn/a6.1×n/a5.9×−140.8%0.0×n/a
Nanologica AB · OMXSTO:NICAUS$5.29MUS$8.67M2.9×1.6×n/a0.3×34.9%0.3×n/a
VivoSim Labs, Inc. · NASDAQ:VIVSUS$5.29M−US$2.76Mn/a−20.5×n/a0.7×n/a0.1×1.91
Biomerica, Inc. · NASDAQ:BMRAUS$4.97MUS$2.23Mn/a0.5×n/a1.4×−115.5%0.0×0.71
VolitionRx Limited · AMEX:VNRXUS$4.87MUS$9.19Mn/a2.7×n/an/a−698.5%n/a1.52
Boule Diagnostics AB · OMXSTO:BOULUS$4.84MUS$24.70Mn/a0.6×n/a0.3×−4.0%1.3×n/a
BioInfra Co.,Ltd. · KRX:199730US$4.75M−US$509,202n/a−0.0×n/a0.5×−32.3%0.0×n/a
Median of the othersUS$5.29MUS$5.61M2.9×1.6×0.6×−115.5%0.0×1.52

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
7.50 GBX · Analysts' mean
EPS, year to Dec 2026
-0.007 · 1 analyst
Revenue, year to Dec 2026
3.2M · 1 analyst

Team and board

Officers

OfficerRole
Matthew WallsChief Executive Officer
Paul FoulgerChief Financial Officer
Jordi PuigChief Operations Officer

Board

DirectorRole
Bill RhodesIndependent Non-Executive Chairman
Felix FruehNon-Executive Director
Huon GrayIndependent Non-Executive Director
Jordi PuigChief Operations Officer
Matthew WallsChief Executive Officer
Paul FoulgerChief Financial Officer
Sergio OliveroIndependent Non-Executive Director

Events

Open Events

Financings

RaiseDateIn US dollars
Private placement of new Ordinary Shares (Additional Subscription Shares)
Announced: £580,000 · GBX 1 a share
Use of proceeds: Additional funding and a longer cash runway while providing the FDA with updates for the De Novo application for its CARDIO inCode-Score test
Feb 6, 2026US$789,256
New Ordinary Shares (WRAP Retail Offer)
Closed: £200,000 raised · GBX 1 a share · Winterflood Securities Limited
Dealers: Winterflood Securities Limited
Jan 26, 2026US$273,712
Private placement of new ordinary shares (Placing Shares)
Announced: £2.6M · GBX 1 a share · Cavendish Capital Markets Limited +2
Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead), Turner Pope Investments (TPI) Ltd (co-lead)
Use of proceeds: US commercialisation and scale-up, EU and UK expansion, fundraising costs and general working capital
Jan 21, 2026US$3.49M
Private placement of new ordinary shares (Subscription Shares)
Announced: £900,000 · GBX 1 a share
Buyers: Nestor Oller (entities associated with existing shareholder Nestor Oller, with certain Directors, to subscribe for 87,300,000 Subscription Shares raising £0.9 million in aggregate)
Insiders: Certain Directors intend to subscribe alongside entities associated with Nestor Oller
Jan 21, 2026US$1.21M
Private placement of new ordinary shares
Update: Cavendish Capital Markets Limited +1
Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead)
Buyers: Santi-1990 SL (Nestor Oller) (9,459,460 shares)
Mar 3, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue3.08M2.70M2.16M1.43M1.15M960.8K1.92M
Cost of revenue1.54M1.27M1.14M798.0K561.0K437.8K882.2K
Gross profit1.54M1.43M1.02M632.0K593.0K523.0K1.04M
Research and development145.0K334.0K72.0K1.00K
Selling, general and administrative1.75M1.86M7.75M6.27M2.01M1.55M204.8K
Operating income-5.89M-5.13M-7.15M-5.90M-3.53M-1.05M-497.4K
Depreciation and amortization266.0K347.0K351.0K163.0K35.0K22.8K21.2K
EBITDA-5.63M-4.79M-6.80M-5.74M-3.50M-1.03M-476.3K
Interest expense13.0K48.0K48.0K20.0K1.21M8.20K7.97K
Income before tax-5.86M-5.08M-7.02M-5.75M-4.14M-1.05M-512.6K
Income tax-158.0K-649.0K-7.00K-187.0K6.00K116.0K-108.8K
Net income-5.71M-4.43M-7.02M-5.56M-4.14M-1.17M-403.7K
Earnings per share, basic-0.02-0.03-0.07-0.06-0.08-0.01-6.03

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents827.0K1.11M2.48M9.73M14.6M2.00M85.1K
Short-term investments68.0K55.0K42.0K16.0K4.00K2.00K
Receivables948.0K610.0K509.0K614.0K265.0K241.2K301.4K
Inventory73.0K126.0K84.0K20.0K14.0K18.2K-107.6K
Current assets2.04M2.10M3.19M10.5M15.0M2.27M386.6K
Property, plant and equipment1.00M46.0K11.0K7.42K
Goodwill0149.0K149.0K0
Total assets2.38M2.66M4.19M11.8M15.2M2.42M489.1K
Accounts payable1.28M612.0K1.19M1.42M345.0K193.0K386.5K
Current liabilities2.20M1.38M2.50M2.18M831.0K563.5K929.1K
Total debt146.0K234.0K299.0K354.0K330.6K
Total liabilities2.25M1.54M2.90M3.90M1.49M563.5K929.1K
Shareholders' equity124.0K1.13M1.29M7.90M13.7M1.86M-440.0K
Shares outstanding274.3M175.0M95.8M95.8M50.5M114.4M67.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-4.07M-5.17M-7.51M-3.76M-3.02M-1.04M-190.7K
Capital spending-44.0K-49.0K-38.0K-849.0K-145.0K-68.3K-123.7K
Free cash flow-4.11M-5.22M-7.54M-4.61M-3.17M-1.11M-314.4K
Cash from investing-44.0K50.0K136.0K-849.0K-145.0K-68.3K-123.7K
Cash from financing3.64M3.65M-94.0K-47.0K15.9M3.03M400.3K
Change in cash-283.0K-1.37M-7.25M-4.82M12.6M1.92M85.3K

Open Financials

Cap table

Built by 6ix from GENinCode PLC’s releases · as of Feb 6, 2026

Common shares
753,041,137
Fully diluted
753,041,137

Fully diluted

LineShares
Common shares753,041,137

Share count over time

CountShares
Nov 22, 2026753,041,137

Open Cap table

Shareholders

StakeStakeSharesDateFiling
First Equity Limited6.31%47.5MNov 5, 2026TR-1 holding notification (FCA)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bill RhodesIndependent Non-Executive Chairman · Since at least Nov 4, 2026
Felix FruehNon-Executive Director · Since at least Jan 21, 2026
Huon GrayIndependent Non-Executive Director · Since at least Feb 9, 2026
Jordi PuigChief Operations Officer · Since at least Feb 9, 2026
Matthew WallsChief Executive Officer · Since at least Sep 29, 2026
Paul FoulgerChief Financial Officer · Since at least Sep 29, 2026
Sergio OliveroIndependent Non-Executive Director · Since at least Feb 9, 2026

Open People

Log in to ask 6ix AI your own questions about GENinCode PLC.